Noviocell BV is an early stage medical technology company that focuses on the development of the first ever synthetic solution for 3D cell culturing, opening up entirely new avenues in a range of applications, ranging from 3D cell culture to regenerative medicine. Noviocell will build upon its proprietary polyisocyanopeptide (PIC) hydrogels and develop them into easy-to-use solutions for biomedical researchers, biotech and pharma industry and clinicians.

The PIC hydrogels are based on breakthrough research from the internationally highly rated Institute for Molecules and Materials at Radboud University, which has resulted in high-impact publications (Nature, Nature Material and Nature communications).

The potential of 3D cell culturing is evident: never before have we been able to assess the complexity of (human) biology in such a detailed manner. Recent highlights include brain, liver and disease-specific organoids (which especially have shown tremendous value in combination with gene editing technology such as CRISPR/CAS). These will contribute to our understanding of health and disease as well as identification of new therapeutic targets and biomarkers. But to fully leverage the potential of 3D cell culturing it is necessary to address three key bottlenecks: robustness, scalability and clinical use.

The most commonly used matrices are from animal origin. This leads to batch-to-batch variability resulting in inconsistencies in results. Noviocell will build upon its synthetic PIC hydrogels and develop them into easy-to-use solutions. ​The unique combination of tunable biofunctionality and biomechanics of the PIC hydrogel makes it an excellent matrices for 3D cell culture or regenerative medicine.

Noviocell BV will commercialize its proprietary disruptive technology, the PIC hydrogel, incorporated in different products. These products have the potential to:

  • revolutionize the field of stem cell biology research by providing the first synthetic, reversible thermosensitive hydrogel for 3D stem cell culturing that can be modified to meet the needs of every cell type and of every researcher (products for research purposes);
  • accelerate large-scale translational research and provide high-throughput assays for industrial use (products for pre-clinical validation)
  • accelerate personalized medicine by establishing disease-specific 3D cell culture models for drug screening and treatment stratification (products for drug screening)
  • transform the arena of tissue engineering and regenerative medicine by providing the first hydrogel produced according to GMP standards that can be used for a range of tissues and cell types (products for clinical use)